Search clinical trials for: pearl millet

Total 730 results

AstraZeneca

Completed

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Diabetes Mellitus

United States, Hungary, South Africa, Slovakia, Romania, Poland
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (CANVAS-R)

Diabetes Mellitus, Type 2 | Albuminuria

Australia, France, Italy, Poland, Ukraine, United Kingdom, United States, China, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Malaysia, Canada, Netherlands, Korea, Republic of, New Zealand, Brazil, Russian Federation, Puerto... and more
Alkermes, Inc.

Completed

ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry (VICTORY)

Opioid Dependence

United States
Avid Radiopharmaceuticals
Eli Lilly and Company; PRA Health Sciences

Completed

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials (RAmP)

Alzheimer Disease | Cognition Disorders

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings (PEARLS)

HIV Infections

United States, Brazil, Peru, India, Malawi, Haiti, South Africa, Thailand, Zimbabwe
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children

Influenza

Spain, Taiwan, Canada, United States, Mexico
Genzyme, a Sanofi Company

Withdrawn

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

Ovarian Cancer | Fallopian Tube Cancer | Metastatic Cancer | Primary Peritoneal Cavity Cancer

United States
Royal Free Hospital NHS Foundation Trust

Unknown

UK - EHL Outcomes Registry

Hemophilia A | Hemophilia B

United Kingdom
NightBalance

Completed

The POSAtive Study: Study for the Treatment of Positional Obstructive Sleep Apnea

Sleep Apnea Syndromes

United States
GlaxoSmithKline

Completed

Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control

Influenza

Canada
Wake Forest University Health Sciences

Completed

Muscadine Grape Seed Supplementation and Vascular Function

Dietary Supplements

United States
Pearl Therapeutics, Inc.

Withdrawn

To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease
Southwest Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B; North Central Cancer...

Completed

S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer

Lung Cancer

United States, Canada
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
Bristol-Myers Squibb

Completed

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)

Atrial Fibrillation | Atrial Flutter

Australia, Brazil, China, France, Germany, India, Italy, Korea, Republic of, Mexico, Russian Federation, Sweden, Taiwan, Turkey, United States, Hong Kong, Spain, Argentina, Canada, Puerto Rico, Colombia, Denmark, Austria, Belgium, Hun... and more
AbbVie (prior sponsor, Abbott)

Completed

Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood (FIRST)

Coronary Artery Disease | Dyslipidemia | Coronary Heart Disease

United States
GlaxoSmithKline

Completed

A Study In Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Canada, Australia, Philippines, Mexico, Puerto Rico
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PT009001)

Chronic Obstructive Pulmonary Disease

United States
Takeda

Completed

Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) (CARES)

Cardiovascular Disease

United States, Mexico
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

COPD

United States
GlaxoSmithKline

Terminated

Study In Asthma Control

Asthma

Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
AmeriSciences LP
Bio-Medical Consultants, Inc.; Vantage Data Solutions Inc.; Esoterix, Inc.; Dr....

Terminated

Toxicity and Safety Evaluation of an Omega-3 Fatty Acid and a Multivitamin and Antioxidant Nutritional Preparation

Healthy

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

Japan
Novo Nordisk A/S

Completed

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Obesity | Metabolism and Nutrition Disorder

United States, Poland, Israel, Italy, Mexico, Spain, Canada, Denmark, Finland, United Kingdom, France, Netherlands, Austria, Belgium, Argentina, Russian Federation, Serbia, Turkey, Switzerland, Germany, South Africa, Hungary, Hong Kong and more
Boehringer Ingelheim

Completed

Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

Hypertension

United States, Argentina, Canada, Chile, Mexico, Peru
Pearl Network

Completed

Assessing the Effects of Three Oral Care Regimens

Gingivitis | Dental Plaque

United States
Southwest Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo

Breast Cancer

United States
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

United States
Jonathan Pearlman

Completed

Monitoring Movement for Pressure Ulcer Prevention

Pressure Ulcer

United States
Hawaii Pacific Health
Genentech, Inc.

Completed

Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) (PEARL2)

Polypoidal Choroidal Vasculopathy | PCV

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo

Breast Cancer | Fatigue | Neurotoxicity | Neuropathy | Chemotherapeutic Agent Toxicity

United States
Nantes University Hospital

Terminated

How to Collect the Expression of Psychological Suffering of Children Under Two Years? (RESOPSYBB)

Emotional Neglect

France
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Diabetes Mellitus, Type 2

United States, Ukraine, Argentina, Mexico, Romania, South Africa, Korea, Republic of, Russian Federation, Brazil, Puerto Rico, Hungary, Slovakia, Czechia
Pearl Therapeutics, Inc.

Completed

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

Asthma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

Breast Cancer | Metastatic Cancer

United States
Janssen Research & Development, LLC
Janssen Pharmaceuticals

Completed

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Influenza A

United States, Germany, Bulgaria, Canada, Estonia, Latvia, Belgium, Puerto Rico
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

Asthma

United States
University of California, San Francisco
Mount Zion Health Fund

Completed

Prenatal Education About Reducing Labor Stress (PEARLS) (PEARLS)

Labor Pain | Tocophobia

United States
Regeneron Pharmaceuticals

Completed

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1 (PRE-SURGE1)

Intercritical Gout

United States, Canada
Pearl Therapeutics, Inc.

Completed

PT003 MDI Dose Confirmation Study

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, United States, New Zealand
Pearl Therapeutics, Inc.

Completed

Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects

Healthy Volunteers

Australia
Pearl Therapeutics, Inc.

Completed

PK Study of PT003 and PT001 in Japanese Healthy Subjects

COPD

United States
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD
Pearl Therapeutics, Inc.

Completed

Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD

COPD

United States
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Pearl Therapeutics, Inc.

Completed

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Chronic Obstructive Pulmonary Disease (COPD)

United States

Search clinical trials for: pearl millet

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations